NCT06271044Active, not recruiting
a. Reducing Radioiodine Treatment in Papillary Thyroid Cancer. RAILESS
Reducing Radioiodine Treatment in Low Risk Papillary Thyroid Cancer
Source: ClinicalTrials.gov · Last updated 21 Feb 2024
Brief summary (registry, in English)
To study if its is safe to reduce the amount of postoperative treatments in those patients, who have been operated on because of a low-risk intrathyroidal papillary thyroid cancer with diameter of 11-20mm, and in whom postoperative thyroglobulin levels are of low level.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 61 (actual)
- First submitted
- 14 Feb 2024
- Start date
- Oct 2014
- Primary completion date
- Dec 2024
- Lead sponsor
- Helsinki University Central Hospital
- Diseases
- Thyroid cancer
- NCT number
- NCT06271044
What you commit to
- Study type: Interventional
- Participants enrolled: 61
- From Oct 2014 to the primary completion date, Dec 2024
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- high risk papillary cancer
- mutlifocal papillary cancer
Who the study is looking for
- low risk papillary intrathyroidal thyroid cancer with diameter of 11-20mm
- no lymphnode metastases
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.